Research effects
Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It achieves potent glycemic and weight control by activating GLP-1 receptors, promoting glucose-dependent insulin secretion, suppressing glucagon release, delaying gastric emptying, and enhancing satiety. Large-scale trials confirm its robust efficacy in weight reduction, glycemic control, and cardiovascular protection. Its cardioprotective mechanisms involve multi-pathway effects including inhibition of oxidative stress, inflammation, apoptosis, and fibrosis. Semaglutide also improves lipid profiles, reduces blood pressure, and provides additional benefits in heart failure, chronic kidney disease, and fatty liver disease. Regarding lean mass loss associated with weight reduction, current evidence indicates weight loss derives predominantly from adipose tissue, with an overall improvement in body composition.
